Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

SIMPLE SUMMARY: Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattaneo, Chiara, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Itri, Federico, Weinbergerová, Barbora, Gomes Da Silva, Maria, Dargenio, Michelina, Dávila-Valls, Julio, Martín-Pérez, Sonia, Farina, Francesca, Van Doesum, Jaap, Valković, Toni, Besson, Caroline, Poulsen, Christian Bjørn, López-García, Alberto, Žák, Pavel, Schönlein, Martin, Piukovics, Klára, Jaksic, Ozren, Cabirta, Alba, Ali, Natasha, Sili, Uluhan, Fracchiolla, Nicola, Dragonetti, Giulia, Adžić-Vukičević, Tatjana, Marchetti, Monia, Machado, Marina, Glenthøj, Andreas, Finizio, Olimpia, Demirkan, Fatih, Blennow, Ola, Tisi, Maria Chiara, Omrani, Ali S., Navrátil, Milan, Ráčil, Zdeněk, Novák, Jan, Magliano, Gabriele, Jiménez, Moraima, Garcia-Vidal, Carolina, Erben, Nurettin, Del Principe, Maria Ilaria, Buquicchio, Caterina, Bergantim, Rui, Batinić, Josip, Al-Khabori, Murtadha, Verga, Luisa, Szotkowski, Tomáš, Samarkos, Michail, Ormazabal-Vélez, Irati, Meers, Stef, Maertens, Johan, Pinczés, László Imre, Hoenigl, Martin, Drgoňa, Ľuboš, Cuccaro, Annarosa, Bilgin, Yavuz M., Aujayeb, Avinash, Rahimli, Laman, Gräfe, Stefanie, Sciumè, Mariarita, Mladenović, Miloš, Çolak, Gökçe Melis, Sacchi, Maria Vittoria, Nordlander, Anna, Berg Venemyr, Caroline, Hanáková, Michaela, García-Poutón, Nicole, Emarah, Ziad, Zambrotta, Giovanni Paolo Maria, Nunes Rodrigues, Raquel, Cordoba, Raul, Méndez, Gustavo-Adolfo, Biernat, Monika M., Cornely, Oliver A., Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688278/
https://www.ncbi.nlm.nih.gov/pubmed/36428621
http://dx.doi.org/10.3390/cancers14225530
Descripción
Sumario:SIMPLE SUMMARY: Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, ≥2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. ABSTRACT: Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Ejemplares similares